Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
نویسندگان
چکیده
منابع مشابه
Immunogenicity of therapeutic proteins.
A year ago Nicole Casadevall of the Hotel-Dieu in Paris and her colleagues published their first 13 cases of pure red-cell aplasia (PRCA) associated with the use of erythropoietin (Epo) in patients with chronic renal failure [1]. As of November 2002, the number of antibody-mediated reported cases in Europe, Canada and Australia has increased to more than 175. The most likely explanation for thi...
متن کاملUnraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins
Biologics have emerged as a powerful and diverse class of molecular and cell-based therapies that are capable of replacing enzymes, editing genomes, targeting tumors, and more. As this complex array of tools arises a distinct set of challenges is rarely encountered in the development of small molecule therapies. Biotherapeutics tend to be big, bulky, polar molecules comprised of protein and/or ...
متن کاملRecent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development
Copyright © 2016 Yanmei Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Biologics such as monoclonal antibodies, recombinant proteins , and novel protein scaffolds can elicit an unwanted immune response in patients. This...
متن کاملFactors influencing the immunogenicity of therapeutic proteins.
Several diseases and disorders are treatable with therapeutic proteins, but some of these products may induce an immune response, especially when administered as multiple doses over prolonged periods. Antibodies are created by classical immune reactions or by the breakdown of immune tolerance; the latter is characteristic of human homologue products. Many factors influence the immunogenicity of...
متن کاملRationally engineered therapeutic proteins with reduced immunogenicity.
Chronic administration of protein therapeutics may elicit unacceptable immune responses to the specific protein. Our hypothesis is that the immunogenicity of protein drugs can be ascribed to a few immunodominant helper T lymphocyte (HTL) epitopes, and that reducing the MHC binding affinity of these HTL epitopes contained within these proteins can generate drugs with lower immunogenicity. To tes...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The AAPS Journal
سال: 2012
ISSN: 1550-7416
DOI: 10.1208/s12248-012-9340-y